TFDP2: Transcription Factor Dp-2 (E2F Dimerization Partner 2)
A key regulator of cell cycle progression and transcriptional control, implicated in cancer and developmental disorders.
Gene Information Card
| Symbol | TFDP2 |
|---|---|
| Full Name | Transcription factor Dp-2 |
| Gene Type | Protein coding |
| Chromosomal Location | 3q23 |
| NCBI Gene ID | 7029 ncbi.nlm.nih.gov/gene/7029 |
| Ensembl ID | ENSG00000114126 |
| UniProt ID | Q14188 |
| OMIM ID | 602160 |
| HGNC ID | 11749 |
| Aliases | DP2, Dp-2, E2F dimerization partner 2 |
Description
TFDP2 (Transcription factor Dp-2) encodes a member of the DP family of transcription factors that heterodimerize with E2F proteins to regulate genes involved in cell cycle progression, DNA replication, and apoptosis. The protein forms complexes with E2F1–E2F6, modulating transcriptional activation or repression depending on the cellular context. TFDP2 is ubiquitously expressed and plays a critical role in development and tumorigenesis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Dysregulation of E2F/DP complexes leads to uncontrolled cell proliferation; TFDP2 overexpression or amplification observed in some tumors. | COSMIC, ClinVar |
| Developmental disorders | Altered TFDP2 expression may disrupt normal cell cycle control during embryogenesis. | OMIM, NCBI Gene |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | High |
| Lymph node | 8.3 | Medium |
| Brain | 6.1 | Medium |
| Liver | 4.2 | Low |
| Heart | 3.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 9.7 | Cervical cancer cell line |
| K562 | 7.4 | Leukemia cell line |
| A549 | 6.8 | Lung cancer cell line |
| MCF7 | 5.2 | Breast cancer cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | Missense | Rare | Unknown functional impact |
| c.200C>T | Nonsense | Rare | Predicted loss of function |
| Amplification | Copy number gain | Observed in multiple cancers | Potential oncogenic effect |
Mutation functional classification
Loss of Function (LOF)
Nonsense or frameshift mutations that truncate the protein, impairing dimerization with E2F and transcriptional activity.
Gain of Function (GOF)
Amplification or overexpression leading to increased E2F target gene activation and enhanced cell proliferation.
Dominant Negative (DN)
Mutations that produce a truncated DP2 protein capable of binding E2F but unable to activate transcription, thereby inhibiting normal E2F/DP function.
View complete mutation data：
Gene Ontology (GO)
| • GO:0000981 (GO:0000981) | • GO:0005515 (GO:0005515) |
| • GO:0005634 (GO:0005634) | • GO:0006357 (GO:0006357) |
| • GO:0007049 (GO:0007049) |
Pathways
• Cell Cycle (KEGG hsa04110)
• E2F transcription factor network (Reactome R-HSA-8953897)
• p53 signaling pathway (KEGG hsa04115)
Protein Summary
The TFDP2 protein (UniProt Q14188) is 410 amino acids long and contains a conserved DP domain required for heterodimerization with E2F transcription factors. It localizes to the nucleus and regulates expression of genes controlling G1/S transition. Post-translational modifications include phosphorylation, which modulates its activity and stability.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TFDP2 Knockout HEK293 Cell Line | EDJ-KQ5921 | Human | 7029 | Details Get a Quote |
| TFDP2 Knockout HeLa Cell Line | EDJ-KQ28179 | Human | 7029 | Details Get a Quote |
| TFDP2 Knockout A-549 Cell Line | EDJ-KQ29456 | Human | 7029 | Details Get a Quote |
| TFDP2 Knockout HCT 116 Cell Line | EDJ-KQ29457 | Human | 7029 | Details Get a Quote |
